LXRX - Lexicon Pharmaceuticals Inc. (LXRX) Q1 2024 Earnings Call Transcript
2024-05-05 05:14:07 ET
Lexicon Pharmaceuticals, Inc. (LXRX)
Q1 2024 Earnings Conference Call
May 2, 2024 05:00 PM ET
Company Participants
Lisa DeFrancesco - Head of Investor Relations and Strategy
Lonnel Coats - Chief Executive Officer and Director
Jeffrey Wade - President and Chief Financial Officer
Craig Granowitz - Senior Vice President and Chief Medical Officer
Tom Garner - Senior Vice President and Chief Commercial Officer
Alan Main - Executive Vice President of Innovation & Chemical Sciences
Conference Call Participants
John Geelan - Piper Sandler
Roanna Ruiz - Leerink Partners
Andrew Tsai - Jefferies
Joseph Stringer - Needham & Company
Presentation
Operator
Good day, everyone, and welcome to the Lexicon Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time all participants are in a listen-only mode. Following management's prepared remarks, we will hold a brief question-and-answer session. As a reminder, this call is being recorded today, May 2, 2024.
I'll now turn the call over to Lisa DeFrancesco, Head of Investor Relations and Strategy for Lexicon. Please go ahead, Lisa.
Lisa DeFrancesco
Thank you, Jamie. Good afternoon, and welcome to the Lexicon Pharmaceuticals First Quarter 2024 Financial Results Conference Call. Joining me today are Lonnel Coats, Lexicon's Chief Executive Officer and Director; Jeff Wade, Lexicon's President and Chief Financial Officer; Dr. Craig Granowitz, Lexicon's Senior Vice President and Chief Medical Officer; and Tom Garner, Lexicon's Senior Vice President and Chief Commercial Officer.
Earlier this afternoon, Lexicon issued a press release announcing financial results for the first quarter of 2024, which is available on our website at www.lexpharma.com and through our SEC filings. A webcast of this call, along with a slide presentation, is available on our website. During this call, we will review the information provided in the release, provide a corporate update and then use the remainder of our time to answer your questions.
Before we begin, let me remind you that we will be making forward-looking statements, including statements related to the safety, efficacy, clinical development, regulatory status and therapeutic and commercial potential of INPEFA, sotagliflozin, Zynquista, LX9211, LX9851 and our other drug programs. These statements may also include characterizations and projections relating to our commercial launch of INPEFA in heart failure as well as the clinical development, regulatory status and market opportunity for all of our drug programs.
This call may also contain forward-looking statements relating to our growth and future operating results, discovery and development of our drug candidates, strategic alliances and intellectual property as well as other matters that are not historical facts or information. Various risks may cause our actual results to differ materially from those expressed or implied in such forward-looking statements. These risks include uncertainties related to our commercial launch of INPEFA, our discussions with the FDA and other regulatory authorities regarding our drug programs, the timing and results of clinical trials and preclinical studies of our drug candidates. Our dependence upon strategic alliances and other third-party relationships, our ability to obtain patent protection for our discoveries, limitations imposed by patents owned or controlled by third parties and the requirement of substantial funding to conduct our planned research, development and commercialization activities....
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2024 Earnings Call Transcript